LONDON - U.S. pharmaceutical giant Pfizer is set to raise $10.6 billion through the sale of a four-part bond, IFR reported on Tuesday, that will help finance its purchase of Wyeth.

The final terms on the four-year bond was set at 1.85 billion euros ($2.6 billion) with guidance set at mid-swaps plus 120 basis points, at the tight end of an initial 120 to 130 basis points range, said IFR Markets, a Thomson Reuters online news and market analysis service.

The seven-year and 12-year bonds were each set at 2 billion euros and guidance was refined to mid-swaps plus 155 basis points and mid-swaps plus 195 basis points respectively. Both came in at the tight end of initial guidance ranges.

The sterling bond was set at 1.5 billion pounds ($2.4 billion) and guidance was set at gilts plus 195 basis points, also at the tight end of the initial 195 to 205 basis point range, added IFR.

Bank of America/Merrill Lynch, Barclays, Citigroup, Goldman Sachs and JP Morgan are managing the sale of the Pfizer bond.

Pfizer is rated Aa2 by Moody's Investors Service, triple-A by Standard & Poor's and AA by Fitch Ratings. ($1=.7158 Euro) ($1=.6288 Pound)

(Reporting by Natalie Harrison)